Jill Herendeen, PharmD

Jill Herendeen is a seasoned regulatory affairs leader with more than 20 years of experience in drug development, specializing in innovative oncology therapeutics that address areas of high unmet need. She has played a pivotal role in the development and global commercialization of multiple oncology therapeutics, including Vectibix®, Opdivo®, and Imbruvica®.

Her expertise spans the full spectrum of drug development—early- and late-stage programs through post-marketing—across modalities such as small molecules, biologics, cellular therapies, and companion diagnostics. Jill’s experience extends beyond regulatory sciences into pharmacovigilance, clinical operations, clinical quality assurance, program management, and alliance management, giving her a comprehensive view of the drug development lifecycle.

Jill began her career at Amgen and went on to hold senior regulatory leadership positions at Bristol Myers Squibb, Pharmacyclics (acquired by AbbVie), Silverback Therapeutics, and Orca Bio.

Most recently, she founded Rubicon Consulting, a regulatory consulting firm dedicated to helping biopharmaceutical companies design and execute regulatory strategies that align with their vision for product development. Through Rubicon, Jill partners with clients to navigate complex regulatory pathways and ultimately maximize patient access to innovative therapies.

Jill holds a BS in Biology from Gonzaga University and a PharmD from University of Washington and completed a general medicine and oncology residency at University of North Carolina Chapel Hill and drug development fellowship at University of North Carolina Chapel Hill and GlaxoSmithKline.